GlycoNex

GlycoNex Current Assets

The Current Assets of GlycoNex (4168.TWO) as of Nov 5, 2026 is 435,000.00 TWD. In the previous year, Current Assets was 31.52 M TWD — a change of -98.62% (lower).

Current Assets

435,000.00TWD

YoY

-98.62%

Last updated:

Current Assets of GlycoNex is 2025 435,000.00 TWD. Current Assets of GlycoNex was 2024 31.52 M TWD. It decreases by -98.62% lower compared to the previous year.

The GlycoNex Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
800,000.00 TWD
Jan 1, 2019
371,000.00 TWD
Jan 1, 2020
479.56 M TWD
Jan 1, 2021
333.16 M TWD
Jan 1, 2022
683.65 M TWD
Jan 1, 2023
706.48 M TWD
Jan 1, 2024
31.52 M TWD
Jan 1, 2025
435,000.00 TWD
The GlycoNex Current Assets history
YEARCurrent AssetsYoY
435,000.00TWD-98.62%
31.52 MTWD-95.54%
706.48 MTWD+3.34%
683.65 MTWD+105.20%
333.16 MTWD-30.53%
479.56 MTWD+129,160.11%
371,000.00TWD-53.63%
800,000.00TWD-62.14%
2.11 MTWD-99.77%
929.12 MTWD-16.07%
1.11 BTWD-42.67%
1.93 BTWD-0.85%
1.95 BTWD+155.22%
763.06 MTWD+133.73%
326.47 MTWD+151.57%
129.77 MTWD+7.32%
120.92 MTWD+290.98%
30.93 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Current Assets of GlycoNex is 435,000.00 TWD in 2025.

Current Assets of GlycoNex changed from 31.52 M TWD to 435,000.00 TWD, representing a -98.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets GlycoNex since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's GlycoNex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GlycoNex

All Key Metrics — GlycoNex